Moderna, Inc.
https://www.modernatx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Moderna, Inc.
Another Boost For Valneva and Pfizer Lyme Disease Vaccine
While they wait for the results from their Phase III study, the partners have posted more impressive mid-stage data on what could be the first approved vaccine for a couple of decades to protect against infection from ticks.
Navigator Medicines Emerges With $100m, Autoimmune Candidate
Backed by Forbion and RA Capital, Navigator will focus on novel OX40-targeted therapies for autoimmune diseases, with a clinical candidate in-licensed from IMBiologics.
New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
2023-2024 Global Biopharma R&D Productivity And Growth Ranking
The overall R&D productivity of the 30 largest public biopharma companies has increased despite a challenging global environment for investment and growth. Will hype cycles impact this picture in coming years?
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
-
Drug Discovery Technologies
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Caperna LLC
- Moderna Therapeutics, Inc.
- Moderna LLC
- Newco LS18, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice